Radioisotope Production (Iodine-131)

I-131 decays by beta emission and gamma emission with a half-life of 8.02 days. It is typically produced in nuclear reactors by neutron irradiation of tellurium. The resulting I-131 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of nuclear reactors, tellurium targets, and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials. Accessibility for developing countries is influenced by the specialised facilities and regulatory requirements.

I-123 production and application are well-established, with widespread use in nuclear medicine.

I-131 is a radioactive isotope that emits beta and gamma radiation, requiring careful handling procedures and physical shielding to minimise radiation exposure.

All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical.

Due to the absence of nuclear materials, IAEA safeguards are not applicable.